[1]张薇,陈华剑.蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响 [J].第三军医大学学报,2019,41(13):1232-1238.
 ZHANG Wei,CHEN Huajian.Effect of protease activated receptor 2 on proliferation and apoptosis of hepatocellular carcinoma cells[J].J Third Mil Med Univ,2019,41(13):1232-1238.
点击复制

蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响
 
(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第13期
页码:
1232-1238
栏目:
基础医学
出版日期:
2019-07-15

文章信息/Info

Title:
Effect of protease activated receptor 2 on proliferation and apoptosis of hepatocellular carcinoma cells
作者:
张薇陈华剑
重庆市急救医疗中心检验科
Author(s):
ZHANG Wei CHEN Huajian

Department of Clinical Laboratory, Chongqing Emergency Medical Center, Chongqing, 400014, China

关键词:
蛋白酶激活受体2肝癌细胞细胞增殖细胞凋亡
Keywords:
protease activated receptor 2 hepatocellular carcinoma cells cell proliferation cell apoptosis
分类号:
R394.3;R730.23;R735.7
文献标志码:
A
摘要:

目的探讨蛋白酶激活受体2(protease activated receptor 2,PAR2)对肝癌细胞增殖及凋亡的影响。方法RT-qPCR检测100例肝癌组织及相应的癌旁组织中PAR2 mRNA的表达,并分析肝癌患者临床病理参数与PAR2表达水平之间的相关性。RT-qPCR及Western blot检测原代肝细胞、永生化肝细胞及肝癌细胞中PAR2 mRNA及蛋白的表达。采用siRNA靶向沉默PAR2的表达,MTS法及软琼脂集落形成实验检测沉默PAR2对肝癌细胞增殖的影响,流式细胞术及PARP的剪切检测沉默PAR2对肝癌细胞凋亡的影响。RT-qPCR筛选PAR2调控的凋亡靶基因,并用Western blot进行验证。结果肝癌组织中PAR2 mRNA的相对表达量为(1.86±1.26),明显高于癌旁组织(0.96±0.66,P<0.001),且PAR2在肝癌组织中表达上调与肿瘤的长径以及分期均相关(P=0.002)。PAR2在肝癌细胞中的表达高于永生化肝细胞和原代肝细胞(P<0.05)。沉默PAR2抑制肝癌细胞SK-Hep-1和PLC/PRF/5的活性(P<0.01)及集落形成能力(P<0.01),沉默PAR2导致SK-Hep-1和PLC/PRF/5细胞凋亡比例分别增加109%(P<0.01)和112%(P<0.01);且沉默PAR2增加了Bax mRNA和蛋白表达水平。结论PAR2可通过影响Bax的表达而影响肝癌细胞的增殖与凋亡。

Abstract:

ObjectiveTo demonstrate the role of protease activated receptor 2 (PAR2) in the proliferation and apoptosis of hepatocellular carcinoma (HCC) cells. MethodsFirstly, the mRNA expression level of PAR2 in the cancer and para-cancerous tissues of 100 HCC patients were detected by RT-qPCR. Then the association between multiple clinicopathologic parameters and PAR2 mRNA level in HCC tissues were illustrated by statistical analysis. Secondly, the mRNA and protein levels of PAR2 in primary hepatocyte (PHH cells), immortalized hepatocyte (MIHA cells) and hepatoma cell lines (PLC/PRF/5, SK-Hep-1, HepG2 and Hep3B) were determined by RT-qPCR and Western blotting. Thirdly, the proliferation of HCC cells was analyzed by MTS and soft agar assay after the silence of PAR2. Moreover, the apoptosis of HCC cells was analyzed by flow cytometry and the cleavage of PARP after the silence of PAR2. Finally, the apoptosis target genes were screened by RT-qPCR, and then validated by Western blotting. ResultsThe relative mRNA level of PAR2 was 1.86±1.26 in HCC tissues, which was significantly higher than that in the adjacent tissues (0.96±0.66, P<0.001), and the up-regulation of PAR2 in HCC tissues was positively correlated with tumor size and tumor stage (P=0.002). Also, the expression level of PAR2 in hepatoma cell lines was significantly higher than those in immortalized hepatocytes and primary hepatocytes (P<0.05). Importantly, silence of PAR2 inhibited the cell viability and colony forming ability in SK-Hep-1 and PLC/PRF/5 cells (both P<0.01), and also induced the apoptotic rate increased to 109% and 112% in SK-Hep-1 and PLC/PRF/5 cells (P<0.01), separately. What’s more, the silence of PAR2 up-regulate the expression of Bax at mRNA and protein levels. ConclusionPAR2  affects the proliferation and apoptosis of HCC cells through regulating the expression of Bax.

参考文献/References:

[1]BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]HASSAN M, WATARI H, ABUALMAATY A, et al. Apoptosis and molecular targeting therapy in cancer[J]. Biomed Res Int, 2014, 2014: 150845. DOI:10.1155/2014/150845.
[3]MCCULLOCH K, MCGRATH S, HUESA C, et al. Rheumatic disease: protease-activated receptor-2 in synovial joint pathobiology[J]. Front Endocrinol (Lausanne), 2018, 9: 257. DOI:10.3389/fendo.2018.00257.
[4]UNGEFROREN H, GIESELER F, KAUFMANN R, et al. Signaling crosstalk of TGF-β/ALK5 and PAR2/PAR1: A complex regulatory network controlling fibrosis and cancer[J]. Int J Mol Sci, 2018, 19(6): E1568. DOI:10.3390/ijms19061568.
[5]POSMA J J, GROVER S P, HISADA Y, et al. Roles of coagulation proteases and PARs (protease-activated receptors) in mouse models of inflammatory diseases[J]. Arterioscler Thromb Vasc Biol, 2019, 39(1): 13-24. DOI:10.1161/ATVBAHA.118.311655.
[6]DAS K, PRASAD R, ROY S, et al. The protease activated receptor 2 promotes rab5a mediated generation of pro-metastatic microvesicles[J]. Sci Rep, 2018, 8(1): 7357. DOI:10.1038/s41598-018-25725-w.
[7]CARVALHO , HUGO DE ALMEIDA V, RONDON A M R, et al. Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells[J]. Biochem Biophys Res Commun, 2018, 504(1): 270-276. DOI:10.1016/j.bbrc.2018.08.169.
[8]DAS K, PRASAD R, ANSARI S A, et al. Matrix metalloproteinase-2: A key regulator in coagulation proteases mediated human breast cancer progression through autocrine signaling[J]. Biomed Pharmacother, 2018, 105:395-406. DOI:10.1016/j.biopha.2018.05.155.
[9]ZHOU B, ZHOU H, LING S, et al. Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2[J]. Oncol Rep, 2011, 25(2): 503-511. DOI:10.3892/or.2010.1077.
[10]GUO D, ZHOU H, WU Y, et al. Involvement of ERK1/2/NF-kappaB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620[J]. Tumor Biol, 2011, 32(5): 921-930. DOI:10.1007/s13277-011-0194-1.
[11]HUANG S H, LI Y, CHEN H G, et al. Activation of proteinase-activated receptor 2 prevents apoptosis of lung cancer cells[J]. Cancer Invest, 2013, 31(9): 578-581. DOI: 10.3109/07357907.2013.845674.
[12]HAN S, LEE C W, TREVINO J G, et al. Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma[J]. PLoS ONE, 2013, 8(10): e76667. DOI:10.1371/journal.pone.0076667.
[13]PENG W T, SUN W Y, LI X R, et al. Emerging roles of G protein-coupled receptors in hepatocellular carcinoma[J]. Int J Mol Sci, 2018, 19(5): E1366. DOI:10.3390/ijms19051366.
[14]FEIGIN M E, XUE B, HAMMELL M C, et al. G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion[J]. Proc Natl Acad Sci U S A, 2014, 111(11): 4191-4196. DOI:10.1073/pnas.1320239111.
[15]张晓飞,董琼珠,薛裕华,等.蛋白酶激活受体1在癌旁组织中的高表达与肝癌早期患者术后预后不良相关[J].中华肝脏病杂志,2011, 19(4): 266-270. DOI: 10.3760/cma.j.issn.1007-3418.2011.04.009.
ZHANG X F, DONG Q Z, XUE Y H, et al. High expression of thrombin receptor PAR1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma in early stage[J]. Chin J Hepatol, 2011, 19(4): 266-270. DOI: 10.3760/cma.j.issn.1007-3418.2011.04.009.
[16]MUSSBACH F, HENKLEIN P, WESTERMANN M, et al. Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation[J]. J Cancer Res Clin Oncol, 2015, 141(5): 813-825. DOI: 10.1007/s00432-014-1863-4.
[17]CARNEIRO-LOBO T C,LIMA M T,MARIANO-OLIVEIRA A, et al. Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients[J]. Oncol Rep, 2014, 31(2): 679-686. DOI:10.3892/or.2013.2880.
[18]JIANG Y H, YAU M K, LIM J, et al. A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells[J]. J Pharmacol Exp Ther, 2018, 364(2): 246-257. DOI:10.1124/jpet.117.245027.
[19]HUGO DE ALMEIDA V, GUIMARES I D S, ALMENDRA L R, et al. Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer[J]. Oncotarget, 2018, 9(55): 30594-30609. DOI:10.18632/oncotarget.25748.

相似文献/References:

[1]郑文建,梁平,赵弘智.RhoC-siRNA表达载体对肝癌细胞生长速度及侵袭力的影响[J].第三军医大学学报,2007,29(18):1779.
 ZHENG Wen-jian,LIANG Ping,ZHAO Hong-zhi.Role of RhoC-siRNA expression vector on growth velocity and invasiveness of hepatoma carcinoma cells[J].J Third Mil Med Univ,2007,29(13):1779.
[2]彭志红,唐波,杨建民,等.KAI1基因对MHCC97-H肝癌细胞粘附力的影响[J].第三军医大学学报,2005,27(23):2311.
[3]曾柱,龙金华.肝癌细胞对树突状细胞线粒体功能的抑制作用[J].第三军医大学学报,2010,32(09):930.
 Zeng Zhu,Long Jinhua.Hepatocellular carcinoma cells suppress mitochondrial function of dendritic cells in vitro[J].J Third Mil Med Univ,2010,32(13):930.
[4]金哲,王广义,谢淑丽,等.RhoC-siRNA联合Rapamycin抑制人肝癌细胞Bel7402 VEGF表达[J].第三军医大学学报,2011,33(03):321.
[5]王密斯,张荣花,王琳,等.miR-185对肝癌细胞生长增殖及侵袭迁移的影响[J].第三军医大学学报,2016,38(17):1918.
 Wang Misi,Zhang Ronghua,Wang Lin,et al.Effect of miR-185 on proliferation, invasion and migration of hepatocellular carcinoma cells[J].J Third Mil Med Univ,2016,38(13):1918.
[6]李军尧,欧武陵.塞来昔布对人肝癌SMMC-7721细胞的生长抑制作用[J].第三军医大学学报,2004,26(08):0.[doi:10.16016/j.1000-5404.2004.08.010 ]
 LI Jun yao,OU Wu ling.[J].J Third Mil Med Univ,2004,26(13):0.[doi:10.16016/j.1000-5404.2004.08.010 ]
[7]郝萍,王东林.FP启动子调控增强型绿色荧光蛋白在人肝癌细胞中表达的研究[J].第三军医大学学报,2004,26(20):0.[doi:10.16016/j.1000-5404.2004.20.024 ]
 HAO Ping,WANG Dong-lin.[J].J Third Mil Med Univ,2004,26(13):0.[doi:10.16016/j.1000-5404.2004.20.024 ]
[8]司维柯,张广运,马立强,等.苦参碱对HepG2细胞系增殖能力的影响[J].第三军医大学学报,2000,22(05):0.[doi:10.16016/j.1000-5404.2000.05.020 ]
[9]陈文生,刘为纹,顾健人,等.人胰岛素样生长因子Ⅱ型受体反义基因对肝癌细胞恶性表型的影响[J].第三军医大学学报,2001,23(01):0.[doi:10.16016/j.1000-5404.2001.01.006 ]
 CHEN Wen sheng,LIU Wei wen,GU Jian ren,et al.[J].J Third Mil Med Univ,2001,23(13):0.[doi:10.16016/j.1000-5404.2001.01.006 ]
[10]张钢,龙勉,吴泽志,等.肝细胞和肝癌细胞粘弹性的对比研究[J].第三军医大学学报,2001,23(06):0.[doi:10.16016/j.1000-5404.2001.06.063 ]

更新日期/Last Update: 2019-07-08